Staphylococcus Aureus Vaccines: Deviating from the Carol

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2016 Aug 17

PMID 27526714

Citations 46

Authors

Dominique Missiakas

Olaf Schneewind

Affiliations

Soon will be listed here.

Abstract

Staphylococcus aureus, a commensal of the human nasopharynx and skin, also causes invasive disease, most frequently skin and soft tissue infections. Invasive disease caused by drug-resistant strains, designated MRSA (methicillin-resistant S. aureus), is associated with failure of antibiotic therapy and elevated mortality. Here we review polysaccharide-conjugate and subunit vaccines that were designed to prevent S. aureus infection in patients at risk of bacteremia or surgical wound infection but failed to reach their clinical endpoints. We also discuss vaccines with ongoing trials for combinations of polysaccharide-conjugates and subunits. S. aureus colonization and invasive disease are not associated with the development of protective immune responses, which is attributable to a large spectrum of immune evasion factors. Two evasive strategies, assembly of protective fibrin shields via coagulases and protein A-mediated B cell superantigen activity, are discussed as possible vaccine targets. Although correlates for protective immunity are not yet known, opsonophagocytic killing of staphylococci by phagocytic cells offers opportunities to establish such criteria.

Citing Articles

The endothelium at the interface between tissues and in the bloodstream.

Speziale P, Foster T, Arciola C Clin Microbiol Rev. 2025; 38(1):e0009824.

PMID: 39807893 PMC: 11905367. DOI: 10.1128/cmr.00098-24.

Pathobiont-induced suppressive immune imprints thwart T cell vaccine responses.

Hajam I, Tsai C, Gonzalez C, Caldera J, Lazaro Diez M, Du X Nat Commun. 2024; 15(1):10335.

PMID: 39681568 PMC: 11649901. DOI: 10.1038/s41467-024-54644-w.

Nasal microbionts differentially colonize and elicit cytokines in human nasal epithelial organoids.

Boyd A, Kafer L, F Escapa I, Kambal A, Tariq H, Hilsenbeck S bioRxiv. 2024; .

PMID: 39386636 PMC: 11463382. DOI: 10.1101/2024.09.25.614934.

Linking Immune Evasion Mechanisms to Staphylococcal Vaccine Failures.

Hajam I, Liu G Antibiotics (Basel). 2024; 13(5).

PMID: 38786139 PMC: 11117348. DOI: 10.3390/antibiotics13050410.

Vaccination with staphylococcal protein A protects mice against systemic complications of skin infection recurrences.

Mandelli A, Magri G, Tortoli M, Torricelli S, Laera D, Bagnoli F Front Immunol. 2024; 15:1355764.

PMID: 38529283 PMC: 10961379. DOI: 10.3389/fimmu.2024.1355764.

References

Clauditz A, Resch A, Wieland K, Peschel A, Gotz F . Staphyloxanthin plays a role in the fitness of Staphylococcus aureus and its ability to cope with oxidative stress. Infect Immun. 2006; 74(8):4950-3. PMC: 1539600. DOI: 10.1128/IAI.00204-06. View

Fattom A, Schneerson R, Szu S, Vann W, Shiloach J, KARAKAWA W . Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun. 1990; 58(7):2367-74. PMC: 258821. DOI: 10.1128/iai.58.7.2367-2374.1990. View

Frasch C . Recent developments in Neisseria meningitidis group A conjugate vaccines. Expert Opin Biol Ther. 2005; 5(2):273-80. DOI: 10.1517/14712598.5.2.273. View

Friedrich R, Panizzi P, Fuentes-Prior P, Richter K, Verhamme I, Anderson P . Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature. 2003; 425(6957):535-9. DOI: 10.1038/nature01962. View

Thammavongsa V, Kim H, Missiakas D, Schneewind O . Staphylococcal manipulation of host immune responses. Nat Rev Microbiol. 2015; 13(9):529-43. PMC: 4625792. DOI: 10.1038/nrmicro3521. View

Cheng A, McAdow M, Kim H, Bae T, Missiakas D, Schneewind O . Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog. 2010; 6(8):e1001036. PMC: 2916881. DOI: 10.1371/journal.ppat.1001036. View

Peters P, Brooks J, McAllister S, Limbago B, Lowery H, Fosheim G . Methicillin-resistant Staphylococcus aureus colonization of the groin and risk for clinical infection among HIV-infected adults. Emerg Infect Dis. 2013; 19(4):623-9. PMC: 3647417. DOI: 10.3201/eid1904.121353. View

Fattom A, Horwith G, Fuller S, Propst M, Naso R . Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine. 2004; 22(7):880-7. DOI: 10.1016/j.vaccine.2003.11.034. View

Geno K, Gilbert G, Song J, Skovsted I, Klugman K, Jones C . Pneumococcal Capsules and Their Types: Past, Present, and Future. Clin Microbiol Rev. 2015; 28(3):871-99. PMC: 4475641. DOI: 10.1128/CMR.00024-15. View

10.

McCarthy A, Lindsay J . Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions. BMC Microbiol. 2010; 10:173. PMC: 2905362. DOI: 10.1186/1471-2180-10-173. View

11.

Thomer L, Emolo C, Thammavongsa V, Kim H, McAdow M, Yu W . Antibodies against a secreted product of Staphylococcus aureus trigger phagocytic killing. J Exp Med. 2016; 213(3):293-301. PMC: 4813671. DOI: 10.1084/jem.20150074. View

12.

Crossley K, Solliday J . Comparison of rectal swabs and stool cultures for the detection of gastrointestinal carriage of Staphylococcus aureus. J Clin Microbiol. 1980; 11(4):433-4. PMC: 273420. DOI: 10.1128/jcm.11.4.433-434.1980. View

13.

Spellberg B, Daum R . Development of a vaccine against Staphylococcus aureus. Semin Immunopathol. 2011; 34(2):335-48. PMC: 4184131. DOI: 10.1007/s00281-011-0293-5. View

14.

Holt D, Holden M, Tong S, Castillo-Ramirez S, Clarke L, Quail M . A very early-branching Staphylococcus aureus lineage lacking the carotenoid pigment staphyloxanthin. Genome Biol Evol. 2011; 3:881-95. PMC: 3175761. DOI: 10.1093/gbe/evr078. View

15.

Votintseva A, Fung R, Miller R, Knox K, Godwin H, Wyllie D . Prevalence of Staphylococcus aureus protein A (spa) mutants in the community and hospitals in Oxfordshire. BMC Microbiol. 2014; 14:63. PMC: 4007515. DOI: 10.1186/1471-2180-14-63. View

16.

Scully I, Liberator P, Jansen K, Anderson A . Covering all the Bases: Preclinical Development of an Effective Staphylococcus aureus Vaccine. Front Immunol. 2014; 5:109. PMC: 3970019. DOI: 10.3389/fimmu.2014.00109. View

17.

Creech 2nd C, Johnson B, Alsentzer A, Hohenboken M, Edwards K, Talbot 3rd T . Vaccination as infection control: a pilot study to determine the impact of Staphylococcus aureus vaccination on nasal carriage. Vaccine. 2009; 28(1):256-60. DOI: 10.1016/j.vaccine.2009.09.088. View

18.

Pelz A, Wieland K, Putzbach K, Hentschel P, Albert K, Gotz F . Structure and biosynthesis of staphyloxanthin from Staphylococcus aureus. J Biol Chem. 2005; 280(37):32493-8. DOI: 10.1074/jbc.M505070200. View

19.

Forsgren A, Svedjelund A, Wigzell H . Lymphocyte stimulation by protein A of Staphylococcus aureus. Eur J Immunol. 1976; 6(3):207-13. DOI: 10.1002/eji.1830060312. View

20.

Cherry J . Historical review of pertussis and the classical vaccine. J Infect Dis. 1996; 174 Suppl 3:S259-63. DOI: 10.1093/infdis/174.supplement_3.s259. View